|
1
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tol J, Koopman M, Cats A, Rodenburg CJ,
Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ,
Sinnige HA, et al: Chemotherapy, bevacizumab, and cetuximab in
metastatic colorectal cancer. N Engl J Med. 360:563–572. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cremolini C, Loupakis F, Antoniotti C,
Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M,
Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus
bevacizumab as first-line treatment of patients with metastatic
colorectal cancer: Updated overall survival and molecular subgroup
analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.
16:1306–1315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stintzing S, Modest DP, Rossius L, Lerch
MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U,
Al-Batran SE, Heintges T, et al: FIRE-3 investigators: FOLFIRI plus
cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal
cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the
final RAS wild-type subgroup of this randomised open-label phase 3
trial. Lancet Oncol. 17:1426–1434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ciocca DR and Calderwood SK: Heat shock
proteins in cancer: Diagnostic, prognostic, predictive, and
treatment implications. Cell Stress Chaperones. 10:86–103. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paul C, Simon S, Gibert B, Virot S, Manero
F and Arrigo AP: Dynamic processes that reflect anti-apoptotic
strategies set up by HspB1 (Hsp27). Exp Cell Res. 316:1535–1552.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cornford PA, Dodson AR, Parsons KF,
Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y and
Foster CS: Heat shock protein expression independently predicts
clinical outcome in prostate cancer. Cancer Res. 60:7099–7105.
2000.PubMed/NCBI
|
|
8
|
Love S and King RJ: A 27 kDa heat shock
protein that has anomalous prognostic powers in early and advanced
breast cancer. Br J Cancer. 69:743–748. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Langdon SP, Rabiasz GJ, Hirst GL, King RJ,
Hawkins RA, Smyth JF and Miller WR: Expression of the heat shock
protein HSP27 in human ovarian cancer. Clin Cancer Res.
1:1603–1609. 1995.PubMed/NCBI
|
|
10
|
Tsuruta M, Nishibori H, Hasegawa H, Ishii
Y, Endo T, Kubota T, Kitajima M and Kitagawa Y: Heat shock protein
27, a novel regulator of 5-fluorouracil resistance in colon cancer.
Oncol Rep. 20:1165–1172. 2008.PubMed/NCBI
|
|
11
|
Hayashi R, Ishii Y, Ochiai H, Matsunaga A,
Endo T, Hasegawa H and Kitagawa Y: Suppression of heat shock
protein 27 expression promotes 5-fluorouracil sensitivity in colon
cancer cells in a xenograft model. Oncol Rep. 28:1269–1274. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rocchi P, So A, Kojima S, Signaevsky M,
Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K and Gleave M: Heat
shock protein 27 increases after androgen ablation and plays a
cytoprotective role in hormone-refractory prostate cancer. Cancer
Res. 64:6595–6602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zellweger T, Miyake H, July LV, Akbari M,
Kiyama S and Gleave ME: Chemosensitization of human renal cell
cancer using antisense oligonucleotides targeting the antiapoptotic
gene clusterin. Neoplasia. 3:360–367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kamada M, So A, Muramaki M, Rocchi P,
Beraldi E and Gleave M: Hsp27 knockdown using nucleotide-based
therapies inhibit tumor growth and enhance chemotherapy in human
bladder cancer cells. Mol Cancer Ther. 6:299–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baylot V, Andrieu C, Katsogiannou M, Taieb
D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C,
et al: OGX-427 inhibits tumor progression and enhances gemcitabine
chemotherapy in pancreatic cancer. Cell Death Dis. 2:e2212011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chi KN, Yu EY, Jacobs C, Bazov J,
Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS
and Hotte SJ: A phase I dose-escalation study of apatorsen
(OGX-427), an antisense inhibitor targeting heat shock protein 27
(Hsp27), in patients with castration-resistant prostate cancer and
other advanced cancers. Ann Oncol. 27:1116–1122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamamoto K, Okamoto A, Isonishi S, Ochiai
K and Ohtake Y: Heat shock protein 27 was up-regulated in cisplatin
resistant human ovarian tumor cell line and associated with the
cisplatin resistance. Cancer Lett. 168:173–181. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamauchi T, Watanabe M, Hasegawa H,
Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T and
Kitajima M: The potential for a selective cyclooxygenase-2
inhibitor in the prevention of liver metastasis in human colorectal
cancer. Anticancer Res. 23(1A): 1–249. 2003.PubMed/NCBI
|
|
19
|
Kadota Y, Yagi H, Inomata K, Matsubara K,
Hibi T, Abe Y, Kitago M, Shinoda M, Obara H, Itano O, et al:
Mesenchymal stem cells support hepatocyte function in engineered
liver grafts. Organogenesis. 10:268–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kleinman ME, Yamada K, Takeda A,
Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S,
Itaya M, Pan Y, et al: Sequence- and target-independent
angiogenesis suppression by siRNA via TLR3. Nature. 452:591–597.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Asami Y, Yoshioka K, Nishina K, Nagata T
and Yokota T: Drug delivery system of therapeutic oligonucleotides.
Drug Discov Ther. 10:256–262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zoubeidi A, Zardan A, Beraldi E, Fazli L,
Sowery R, Rennie P, Nelson C and Gleave M: Cooperative interactions
between androgen receptor (AR) and heat-shock protein 27 facilitate
AR transcriptional activity. Cancer Res. 67:10455–10465. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shiota M, Bishop JL, Nip KM, Zardan A,
Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, et
al: Hsp27 regulates epithelial mesenchymal transition, metastasis,
and circulating tumor cells in prostate cancer. Cancer Res.
73:3109–3119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rocchi P, Beraldi E, Ettinger S, Fazli L,
Vessella RL, Nelson C and Gleave M: Increased Hsp27 after androgen
ablation facilitates androgen-independent progression in prostate
cancer via signal transducers and activators of transcription
3-mediated suppression of apoptosis. Cancer Res. 65:11083–11093.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Concannon CG, Orrenius S and Samali A:
Hsp27 inhibits cytochrome c-mediated caspase activation by
sequestering both pro-caspase-3 and cytochrome c. Gene Expr.
9:195–201. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garrido C, Ottavi P, Fromentin A, Hammann
A, Arrigo AP, Chauffert B and Mehlen P: HSP27 as a mediator of
confluence-dependent resistance to cell death induced by anticancer
drugs. Cancer Res. 57:2661–2667. 1997.PubMed/NCBI
|
|
27
|
Rogalla T, Ehrnsperger M, Preville X,
Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo AP,
Buchner J, et al: Regulation of Hsp27 oligomerization, chaperone
function, and protective activity against oxidative stress/tumor
necrosis factor alpha by phosphorylation. J Biol Chem.
274:18947–18956. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wyttenbach A, Sauvageot O, Carmichael J,
Diaz-Latoud C, Arrigo AP and Rubinsztein DC: Heat shock protein 27
prevents cellular polyglutamine toxicity and suppresses the
increase of reactive oxygen species caused by huntingtin. Hum Mol
Genet. 11:1137–1151. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garrido C, Schmitt E, Candé C, Vahsen N,
Parcellier A and Kroemer G: HSP27 and HSP70: Potentially oncogenic
apoptosis inhibitors. Cell Cycle. 2:579–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kluck RM, Bossy-Wetzel E, Green DR and
Newmeyer DD: The release of cytochrome c from mitochondria: A
primary site for Bcl-2 regulation of apoptosis. Science.
275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsunaga A, Ishii Y, Tsuruta M,
Okabayashi K, Hasegawa H and Kitagawa Y: Inhibition of heat shock
protein 27 phosphorylation promotes sensitivity to 5-fluorouracil
in colorectal cancer cells. Oncol Lett. 8:2496–2500. 2014.
View Article : Google Scholar : PubMed/NCBI
|
